Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 11/2011

Open Access 01-11-2011 | Article

Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis

Authors: A. E. Hogan, A. M. Tobin, T. Ahern, M. A. Corrigan, G. Gaoatswe, R. Jackson, V. O’Reilly, L. Lynch, D. G. Doherty, P. N. Moynagh, B. Kirby, J. O’Connell, D. O’Shea

Published in: Diabetologia | Issue 11/2011

Login to get access

Abstract

Aims/hypothesis

The innate immune cells, invariant natural killer T cells (iNKT cells), are implicated in the pathogenesis of psoriasis, an inflammatory condition associated with obesity and other metabolic diseases, such as diabetes and dyslipidaemia. We observed an improvement in psoriasis severity in a patient within days of starting treatment with an incretin-mimetic, glucagon-like peptide-1 (GLP-1) receptor agonist. This was independent of change in glycaemic control. We proposed that this unexpected clinical outcome resulted from a direct effect of GLP-1 on iNKT cells.

Methods

We measured circulating and psoriatic plaque iNKT cell numbers in two patients with type 2 diabetes and psoriasis before and after commencing GLP-1 analogue therapy. In addition, we investigated the in vitro effects of GLP-1 on iNKT cells and looked for a functional GLP-1 receptor on these cells.

Results

The Psoriasis Area and Severity Index improved in both patients following 6 weeks of GLP-1 analogue therapy. This was associated with an alteration in iNKT cell number, with an increased number in the circulation and a decreased number in psoriatic plaques. The GLP-1 receptor was expressed on iNKT cells, and GLP-1 induced a dose-dependent inhibition of iNKT cell cytokine secretion, but not cytolytic degranulation in vitro.

Conclusions/interpretation

The clinical effect observed and the direct interaction between GLP-1 and the immune system raise the possibility of therapeutic applications for GLP-1 in inflammatory conditions such as psoriasis.
Literature
1.
Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM (2006) Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 55:829–835PubMedCrossRef
2.
Gisondi P, Tessari G, Conti A et al (2007) Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case–control study. Br J Dermatol 157:68–73PubMedCrossRef
3.
Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M (2006) Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 298:321–328PubMedCrossRef
4.
Qureshi AA, Choi HK, Setty AR, Curhan GC (2009) Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol 145:379–382PubMedCrossRef
5.
Wellen KE, Hotamisligil GS (2005) Inflammation, stress, and diabetes. J Clin Invest 115:1111–1119PubMed
6.
Spah F (2008) Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach. Br J Dermatol 159(Suppl 2):10–17PubMedCrossRef
7.
Mallbris L, Akre O, Granath F et al (2004) Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 19:225–230PubMedCrossRef
8.
Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB (2006) Risk of myocardial infarction in patients with psoriasis. JAMA 296:1735–1741PubMedCrossRef
9.
Wilson PW, D’Agostino RB, Sullivan L, Parise H, Kannel WB (2002) Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 162:1867–1872PubMedCrossRef
10.
Lynch LA, O'Connell JM, Kwasnik AK, Cawood TJ, O'Farrelly C, O'Shea DB (2009) Are natural killer cells protecting the metabolically healthy obese patient? Obesity (Silver Spring) 17:601–605CrossRef
11.
Lynch L, O'Shea D, Winter DC, Geoghegan J, Doherty DG, O'Farrelly C (2009) Invariant NKT cells and CD1d(+) cells amass in human omentum and are depleted in patients with cancer and obesity. Eur J Immunol 39:1893–1901PubMedCrossRef
12.
Liu TY, Uemura Y, Suzuki M et al (2008) Distinct subsets of human invariant NKT cells differentially regulate T helper responses via dendritic cells. Eur J Immunol 38:1012–1023PubMedCrossRef
13.
Peternel S, Kastelan M (2009) Immunopathogenesis of psoriasis: focus on natural killer T cells. J Eur Acad Dermatol Venereol 23:1123–1127PubMedCrossRef
14.
Taniguchi M, Tashiro T, Dashtsoodol N, Hongo N, Watarai H (2010) The specialized iNKT cell system recognizes glycolipid antigens and bridges the innate and acquired immune systems with potential applications for cancer therapy. Int Immunol 22:1–6PubMedCrossRef
15.
Molling JW, Langius JA, Langendijk JA et al (2007) Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J Clin Oncol 25:862–868PubMedCrossRef
16.
Tudhope SJ, von Delwig A, Falconer J et al (2010) Profound invariant natural killer T-cell deficiency in inflammatory arthritis. Ann Rheum Dis 69:1873–1879PubMedCrossRef
17.
Kaieda S, Tomi C, Oki S, Yamamura T, Miyake S (2007) Activation of invariant natural killer T cells by synthetic glycolipid ligands suppresses autoantibody-induced arthritis. Arthritis Rheum 56:1836–1845PubMedCrossRef
18.
Girard J (2008) The incretins: from the concept to their use in the treatment of type 2 diabetes. Part A: Incretins: concept and physiological functions. Diabetes Metab 34:550–559PubMedCrossRef
19.
20.
Hadjiyanni I, Baggio LL, Poussier P, Drucker DJ (2008) Exendin-4 modulates diabetes onset in nonobese diabetic mice. Endocrinology 149:1338–1349PubMedCrossRef
21.
Hadjiyanni I, Siminovitch KA, Danska JS, Drucker DJ (2010) Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells. Diabetologia 53:730–740PubMedCrossRef
22.
Marx N, Burgmaier M, Heinz P et al (2010) Glucagon-like peptide-1(1-37) inhibits chemokine-induced migration of human CD4-positive lymphocytes. Cell Mol Life Sci 67:3549–3555PubMedCrossRef
23.
Kim SJ, Nian C, Doudet DJ, McIntosh CH (2009) Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation. Diabetes 58:641–651PubMedCrossRef
24.
Matsuda JL, Mallevaey T, Scott-Browne J, Gapin L (2008) CD1d-restricted iNKT cells, the ‘Swiss-Army knife’ of the immune system. Curr Opin Immunol 20:358–368PubMedCrossRef
25.
Cameron AL, Kirby B, Fei W, Griffiths CE (2002) Natural killer and natural killer-T cells in psoriasis. Arch Dermatol Res 294:363–369PubMed
26.
Cameron AL, Kirby B, Griffiths CE (2003) Circulating natural killer cells in psoriasis. Br J Dermatol 149:160–164PubMedCrossRef
27.
Bonish B, Jullien D, Dutronc Y et al (2000) Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-gamma production by NK-T cells. J Immunol 165:4076–4085PubMed
28.
Nickoloff BJ, Bonish B, Huang BB, Porcelli SA (2000) Characterization of a T cell line bearing natural killer receptors and capable of creating psoriasis in a SCID mouse model system. J Dermatol Sci 24:212–225PubMedCrossRef
29.
Lee PT, Putnam A, Benlagha K, Teyton L, Gottlieb PA, Bendelac A (2002) Testing the NKT cell hypothesis of human IDDM pathogenesis. J Clin Invest 110:793–800PubMed
30.
Shirakawa J, Fujii H, Ohnuma K et al (2011) Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes 60:1246–1257PubMedCrossRef
31.
Chilton R, Wyatt J, Nandish S, Oliveros R, Lujan M (2011) Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies. Am J Med 124:S35–S53PubMedCrossRef
32.
Nikolaidis LA, Mankad S, Sokos GG et al (2004) Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109:962–965PubMedCrossRef
33.
Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M (2008) Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117:2340–2350PubMedCrossRef
34.
Holst JJ, Burcelin R, Nathanson E (2011) Neuroprotective properties of GLP-1: theoretical and practical applications. Curr Med Res Opin 27:547–558PubMedCrossRef
35.
Lerche S, Brock B, Rungby J et al (2008) Glucagon-like peptide-1 inhibits blood–brain glucose transfer in humans. Diabetes 57:325–331PubMedCrossRef
36.
Mcclean PL, Gault VA, Harriott P, Hölscher C (2009) Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer’s disease. Eur J Pharmacol 630:158–162PubMedCrossRef
37.
Kodera R, Shikata K, Kataoka HU et al (2011) Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 54:965–978PubMedCrossRef
38.
Hattori Y, Jojima T, Tomizawa A et al (2010) A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. Diabetologia 53:2256–2263PubMedCrossRef
39.
Suarez-Pinzon WL, Power RF, Yan Y, Wasserfall C, Atkinson M, Rabinovitch A (2008) Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice. Diabetes 57:3281–3288PubMedCrossRef
40.
Zhang J, Tokui Y, Yamagata K et al (2007) Continuous stimulation of human glucagon-like peptide-1 (7-36) amide in a mouse model (NOD) delays onset of autoimmune type 1 diabetes. Diabetologia 50:1900–1909PubMedCrossRef
41.
Xue S, Wasserfall CH, Parker M et al (2008) Exendin-4 therapy in NOD mice with new-onset diabetes increases regulatory T cell frequency. Ann N Y Acad Sci 1150:152–156PubMedCrossRef
42.
Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ (1995) Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44:1126–1131PubMedCrossRef
43.
44.
Mellett M, Atzei P, Jackson R, O’Neill LA, Moynagh PN (2011) Mal mediates TLR-induced activation of CREB and expression of IL-10. J Immunol 186:4925–4935PubMedCrossRef
45.
Lamas O, Martinez JA, Marti A (2004) Energy restriction restores the impaired immune response in overweight (cafeteria) rats. J Nutr Biochem 15:418–425PubMedCrossRef
46.
Tanaka S, Inoue S, Isoda F et al (1993) Impaired immunity in obesity: suppressed but reversible lymphocyte responsiveness. Int J Obes Relat Metab Disord 17:631–636PubMed
47.
Moulin CM, Marguti I, Peron JPS, Halpern A, Rizzo LV (2011) Bariatric surgery reverses natural killer (NK) cell activity and NK-related cytokine synthesis impairment induced by morbid obesity. Obes Surg 21:112–118PubMedCrossRef
48.
Hossler EW, Maroon MS, Mowad CM (2011) Gastric bypass surgery improves psoriasis. J Am Acad Dermatol 65:198–200PubMedCrossRef
49.
Mingrone G (2008) Role of the incretin system in the remission of type 2 diabetes following bariatric surgery. Nutr Metab Cardiovasc Dis 18:574–579PubMedCrossRef
Metadata
Title
Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis
Authors
A. E. Hogan
A. M. Tobin
T. Ahern
M. A. Corrigan
G. Gaoatswe
R. Jackson
V. O’Reilly
L. Lynch
D. G. Doherty
P. N. Moynagh
B. Kirby
J. O’Connell
D. O’Shea
Publication date
01-11-2011
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 11/2011
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-011-2232-3

Other articles of this Issue 11/2011

Diabetologia 11/2011 Go to the issue

Letter

High serum potassium levels after using losartan can reflect more severe renal disease

Article

Subcutaneous thigh fat area is unrelated to risk of type 2 diabetes in a prospective study of Japanese Americans

Erratum

Erratum to: Sphingolipids: agents provocateurs in the pathogenesis of insulin resistance

Article

Trends in population attributable fraction of acute coronary syndrome and ischaemic stroke due to diabetes in Finland

Letter

High serum potassium levels after losartan can reflect more severe renal disease. Reply to Gonçalves AR, El Nahas AM [letter]

Article

Methylglyoxal impairs insulin signalling and insulin action on glucose-induced insulin secretion in the pancreatic beta cell line INS-1E
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits